Quick Answer
Transcode Therapeutics, Inc. reported Total Assets of $7.29 million for fiscal year 2024.
Transcode Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2024 | $7.29M | +41.1% |
| 2023 | $5.17M | -31.9% |
| 2022 | $7.59M | -66.9% |
| 2021 | $22.94M | +2073.5% |
| 2020 | $1.06M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.23M | +32.8% | -36.8% |
| June 30, 2025 | $8.27M | +71.3% | -37.3% |
| March 31, 2025 | $13.19M | +81.0% | +80.9% |
| December 31, 2024 | $7.29M | +41.1% | +85.3% |
| September 30, 2024 | $3.94M | -61.5% | -18.4% |
| June 30, 2024 | $4.82M | -18.0% | -33.8% |
| March 31, 2024 | $7.29M | +30.4% | +41.0% |
| December 31, 2023 | $5.17M | -31.9% | -49.5% |
- Transcode Therapeutics, Inc. showed an increase of +41.1% in Total Assets compared to the prior fiscal year.
- Over the 2020–2024 period, Transcode Therapeutics, Inc.’s total assets has grown by 591.2% (from $1.06 million to $7.29 million).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: